CMS launched a voluntary model to let Medicare Part D plans and state Medicaid programs cover GLP‑1 drugs for weight management, representing a threshold event for obesity drug access in the U.S. The plan allows payers to test coverage pathways that could expand access for older adults and Medicaid beneficiaries. The model aims to resolve coverage barriers that limited Medicare and some Medicaid programs from broadly reimbursing GLP‑1 medicines for chronic weight management. GLP‑1 receptor agonists (a class of incretin‑based drugs used for diabetes and weight management) have driven large market growth; a CMS pilot could materially increase uptake and reshape pharmacy benefit design.